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Mitral regurgitation (MR) is a common valvular heart 
disease and is the second most frequent indication for 
heart valve surgery in Western countries1. Almost 9% 
of the general population aged >75 years in the USA 
have MR2. Cardiac imaging is crucial for diagnosis, 
identifying the cause of the disease, monitoring dis-
ease progression and planning definitive treatment for 
MR3. Echocardiography remains the first- line and most 
widely available imaging test for the assessment of MR. 
Cardiovascular magnetic resonance imaging (CMR) 
has also emerged in the past 20 years as a robust, non-
invasive imaging modality for the assessment of patients 
with MR4. CMR offers a comprehensive evaluation of 
MR and its effects on the heart by providing precise vol-
umetric assessment (using cine images) and myocardial 
scar or fibrosis assessment (using the late gadolinium 
enhancement (LGE) technique). Therefore, CMR is 
often complementary to echocardiography in informing 
the clinical management of MR4.
As more evidence is gathered for the use of CMR in 
the assessment of MR, clinicians and researchers need 
a standard CMR protocol to follow in order to improve 
the consistency of mitral valve assessment. A consistent 
approach will further improve the clinical translation and 
adoption of CMR for the assessment of the mitral valve 
and MR. Although evidence- based data from randomized 
clinical trials are limited for MR assessment, in this 
Consensus Statement we highlight the role of CMR in 
the assessment of MR and provide recommendations for 
a standardized protocol and reporting method.
Methods
A panel of individuals with vast expertise in MR 
assessment by standard and emerging methods of 
CMR gathered in a closed group meeting titled ‘Mitral 
Valve Regurgitation Assessment by Cardiac Magnetic 
Resonance’ held at the joint EuroCMR–Society for 
Cardiovascular Magnetic Resonance (SCMR) meeting in 
Barcelona, Spain, in January 2018. The organizers of the 
meeting (P.G. and J.W.) appointed a scientific committee 
(A.J.S., L.Z., C.-J.C. and T.E.) to discuss the appropriate-
ness of the meeting, clinical needs, topics to be discussed 
and, more importantly, to identify experts in the field 
to cover all aspects relevant to the goal of the meeting. 
The appointment of international experts was decided 
by general agreement among the members of the scien-
tific committee. A follow- up meeting was arranged at 
the Joint Annual Meeting ISMRM–ESMRMB in Paris, 
France, in June 2018. A final teleconference was arranged 
in February 2019, after completion of an electronic 
database search and collection of evidence.
The evidence- based literature was synthesized by 
the following authors: P.G., A.J.S., L.Z. and C.-J.C. They 
searched electronic databases including MEDLINE 
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(PubMed), Embase, the Cochrane library and OpenGray 
up to 8 January 2019, with no restriction on language. 
The search terms included “mitral regurgitation”, “cardio-
vascular magnetic resonance” and “echocardiography”. 
All retrospective and prospective studies that reported 
both CMR and echocardiography of MR were considered 
eligible. In addition, A.J.S. checked the reference lists of 
selected articles for further relevant articles. Review 
articles, case reports, comments and author replies were 
excluded. The final decision on inclusion was reached 
through a consensus of the four screening authors.
The main objectives at the meetings were to appraise 
previous and new lines of evidence on CMR- based 
assessment of the mitral valve, to review available data 
on the diagnostic and prognostic value of CMR in the MR 
setting, and to provide recommendations for the stand-
ardization of imaging protocols for use in clinical trials 
and experimental scenarios. For the consensus recom-
mendations, open discussions took place between all 
experts, and verbal agreements were made. A majority 
of experts had to agree with a statement or recommen-
dation for it to be included in this Consensus Statement. 
This Consensus Statement summarizes the final conclu-
sions and recommendations agreed by the expert panel 
in the meetings.
Current clinical guidelines
The ESC and AHA/ACC guidelines for the management 
of valvular heart disease emphasize the severity of the 
MR in deciding whether patients are eligible for mitral 
valve surgery3,5, while also emphasizing the importance 
of assessing the haemodynamic effects of the MR on the 
left ventricle and left atrium. The AHA/ACC guidelines 
highlight that CMR is an appropriate test in chronic pri-
mary MR to assess ventricular volumes and function or 
even MR severity, especially when these issues are not sat-
isfactorily addressed by transthoracic echocardiography 
(TTE)5. In addition, for chronic secondary MR, CMR is 
indicated to establish and/or to assess myocardial viabil-
ity, which in turn might influence the management of 
functional MR5. Similarly, the ESC guidelines on valvular 
heart disease recommend CMR assessment in patients 
with inadequate TTE imaging for ventricular volume 
and function assessment3. These guidelines do not detail 
several additional areas in which CMR can provide infor-
mation on the aetiology of MR (primary or secondary), 
including the assessment of mitral valve leaflet or scal-
lop function6. Moreover, the guidelines have limited 
recommendations on how to perform comprehensive 
assessment of MR by CMR in a standardized way.
Evidence for CMR to assess MR
CMR is an emerging, noninvasive tool that can provide 
comprehensive assessment of the mitral valve and MR. 
As previously stated, CMR provides excellent accuracy 
and reproducibility in the assessment of ventricular and 
atrial size and function7, allowing for comprehensive 
longitudinal and postoperative assessment of reverse left 
ventricular (LV) remodelling. Studies evaluating the role 
of CMR for the assessment of MR are listed in Table 1. 
A thorough evaluation with the use of cine CMR allows a 
systematic inspection of the anatomy of the mitral valve 
and characterizes the MR, both of which contribute to 
determining the aetiology of the MR8. The severity of the 
MR can be evaluated using several CMR- based quanti-
tative techniques that are detailed below. Furthermore, 
CMR can provide information about the mechanism of 
MR by identifying morphological abnormalities of the 
mitral valve apparatus9,10. The presence of billowing or 
flail segments can be identified by dedicated cine imag-
ing focusing on the different scallops of the mitral valve 
leaflets8. In secondary MR, CMR can provide an accu-
rate assessment of LV dilatation and (dys)function, in 
addition to the identification of myocardial and papillary 
muscle scar formation11.
Clinical outcome studies
Primary MR. In a prospective, multicentre study by 
Myerson and colleagues, 109 asymptomatic patients 
with moderate or severe primary MR defined by echo-
cardiography had CMR scans at baseline and were fol-
lowed up for up to 8 years (mean 2.5 ± 1.9 years)12. CMR 
quantification of MR accurately identified patients who 
progressed to having symptoms or other indications 
for surgery: 91% of participants with a regurgitant vol-
ume ≤55 ml survived to 5 years without surgery com-
pared with only 21% of participants with a regurgitant 
volume >55 ml (P < 0.0001)12. Similar findings were 
observed in a further prospective, dual- centre study 
by Penicka and colleagues in which 258 asymptomatic 
patients with moderate or severe primary MR defined 
by echocardiography underwent CMR and were fol-
lowed up for a median of 5 years13. In this study, the 
researchers demonstrated that CMR- derived MR vol-
ume was the best predictor of mortality (area under 
the curve = 0.72). In addition, when MR volume was 
combined with the development of an indication for 
mitral valve surgery as a clinical outcome, the predic-
tive value increased (area under the curve = 0.83)13. 
The other major finding of this study was that the 
agreement between echocardiography and CMR for 
classifying primary MR was poor for patients with late 
systolic MR or multiple MR jets (both κ < 0.2)13. These 
findings suggest that, in patients who have complex 
primary MR jet physiology, standard CMR quantifi-
cation of MR can offer complementary information to 
that obtained by echocardiography for consideration of 
valvular intervention.
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Table 1 | Studies assessing the use of CMR in MR with or without echocardiography
Study (year) n Prospective study? Correlation (r)a Bias (ml)b
LVSV – AoPC method
2GPKEMCGV|CN
13  Yes  17.1 ±
*GQGV|CN
44 37 Yes 2+5# s±
&XQNWOGVTKE –17.4 ±
&GEJQ ±
*CTTKUGV|CN
  Yes – –
5CEJFGXGV|CN
  Yes  s
sVQ
/[GTUQPGV|CN
  Yes – –
#RNKPGV|CN
47  Yes  11 ±
.QRG\/CVVGKGV|CN
  No  ± 17
7TGVUM[GV|CN
  Yes  
sVQ
$TWIIGTGV|CN
  Yes &61'2+5# s
sVQ
&66'2+5# s
sVQ
%JQKGV|CN
  Yes &66'2+5# s
sVQ
&66'2+5# 
sVQ
8CP&G*G[PKPIGV|CN
  Yes &66'&QRRNGTs 
NKOKVUPQVTGRQTVGF
66'2+5# 
NKOKVUPQVTGRQTVGF
6JCXGPFKTCPCVJCPGV|CN


 Yes &KPVGITCVGF2+5# 
sVQ
&RGCM2+5# 
sVQ
5QPGV|CN
  Yes &2+5# 
sVQ
&8/ 
sVQ
&(8%& 
sVQ
4GFF[GV|CN
 44 Yes – –
%CYNG[GV|CN
  Yes 2+5# s
sVQ
&QRRNGT 
sVQ
*COCFCGV|CN
  Yes '41# 
sVQ
#41#s 
sVQ
5MCWIGV|CN
  Yes  –4.7 ±
5JCPMUGV|CN
43  Yes &66's s
sVQ
&6''s s
sVQ
/[GTUQPGV|CN
  Yes – –
*GNNITGPGV|CN
  Yes – s
sVQ
)CDTKGNGV|CN
  Yes – –
)GNHCPFGV|CN
  Yes – –
-K\KNDCUJGV|CN
  Yes  3 ± 13
*WPFNG[GV|CN
 17 Yes – –
LVSV – RVSV method
5WMRTCRJTWVGGV|CN
31 43 No 2+5# s
sVQ
-QPGV|CN
  No – –
MVPC – AoPC method
2QNVGGV|CN
  Yes – –
$WEMGV|CN
 73 Yes  s±
(WLKVCGV|CN
  Yes – –
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LGE has been reported on CMR images in patients 
with primary MR, especially in those with mitral valve 
prolapse8,14. In addition, in patients with primary MR, 
LGE of papillary muscles is associated with complex ven-
tricular arrhythmias15. Subsequent evidence confirms 
that LV fibrosis indicated by LGE is more prevalent in 
MR with mitral valve prolapse than in patients without 
prolapse, whereas patients with mitral valve prolapse 
and concomitant LV fibrosis have the highest rate of 
arrhythmic events15. Persistent volume overload from 
MR results in impaired LV function and the presence of 
diffuse myocardial fibrosis16. Mitral annulus disjunction 
is an abnormal atrial displacement of the hinge point 
of the mitral valve away from the ventricular myocar-
dium17. Mitral annulus disjunction has been associated 
with mitral valve prolapse and sudden cardiac death 
owing to ventricular arrhythmias9,18.
Secondary MR. A prospective, multicentre study in 
103 patients with either primary or secondary MR 
showed substantial discordance in the severity of MR as 
assessed with either CMR or echocardiography on the 
basis of either the American Society of Echocardiography 
integrated method or the proximal isovelocity surface 
area (PISA)-based regurgitant volume19. In addition, in 
the subset of patients who had mitral valve surgery and 
underwent postoperative CMR, good correlation existed 
between LV remodelling and MR severity as assessed 
by CMR (r = 0.85; P < 0.0001), but not when assessed by 
echocardiography (r = 0.32; P = 0.1), either categorically 
or quantitatively, with the use of the PISA method.
Persistent volume overload from MR results in 
impaired LV function and subsequent myocardial 
fibrosis16. In patients with ischaemic cardiomyopathy 
and severe MR, the presence of severe scarring in the 
region of the posterior papillary muscle, as detected by 
preoperative CMR, can render these patients unsuitable 
for mitral annuloplasty20. Moreover, the extent of myo-
cardial scarring is also informative about the progression 
of ischaemic MR21.
In summary, CMR has become an established non-
invasive imaging modality to assess the severity of MR. 
CMR can be used to phenotype prognostically rele-
vant clinical features that are complementary to those 
identified by echocardiography in patients with MR.
CMR acquisition protocol to assess MR
A CMR study should aim to answer several clinical ques-
tions (box 1) that influence the management of patients 
with MR. A comprehensive MR protocol should assess 
the mitral valve anatomy and function to define the 
cause of the MR — primary (organic) versus second-
ary (functional), LV and right ventricular (RV) volumes 
and function, and quantify the MR (Fig. 1a). However, 
given that TTE, the first- line imaging test, can provide 
information on the aetiology of the MR in the majority 
of patients, we also include a CMR protocol focused on 
MR quantification (Fig. 1b). A decision on whether to use 
Study (year) n Prospective study? Correlation (r)a Bias (ml)b
4D- flow methods
-CORJWKUGV|CN
  No – –
(GPGKUGV|CN
  No &KTGEV –
+PFKTGEV –
%CNMQGPGV|CN
37  Yes s –
4QGUGV|CN
  No – –
/CTUCPGV|CN
  Yes &66' s
sVQ
&66's s
sVQ
9GUVGPDGTIGV|CN
  No – –
Other quantitative methods
)QTQFKUM[GV|CN
  Yes CMR PISA versus echo 
2+5#
–
7TGVUM[GV|CN
  No – –
Nonquantitative methods
*GKVPGTGV|CN
71  No  –
1\FQICPGV|CN
  No – –
$WEJPGTGV|CN
34  Yes %/4'41#XGTUWUGEJQ
'41#
–
#WTKIGOOCGV|CN
73  Yes – –
2HNWIHGNFGTGV|CN
74  Yes – –
#Q2%CQTVKERJCUGEQPVTCUVUVTQMGXQNWOG#41#CPCVQOKECNTGIWTIKVCPVQTKHKEGCTGC%/4ECTFKCEOCIPGVKETGUQPCPEG
KOCIKPIGEJQGEJQECTFKQITCRJ['41#GHHGEVKXGTGIWTIKVCPVQTKHKEGCTGC(8%&HWNNXQNWOGEQNQWT&QRRNGTGEJQECTFKQITCRJ[
LVSV, left ventricular stroke volume; MR , mitral regurgitation; MVPC, mitral valve phase- contrast stroke volume; PISA , proximal 
KUQXGNQEKV[UWTHCEGCTGC4858TKIJVXGPVTKEWNCTUVTQMGXQNWOG61'VTCPUQGUQRJCIGCNGEJQECTFKQITCRJ[66'VTCPUVJQTCEKE
echocardiography ; VM, volumetric quantification method. aBetween echocardiography- determined and CMR- determined MR 
volume. bRegurgitant volume (echocardiography – CMR).
Table 1 | (cont.) Studies assessing the use of CMR in MR with or without echocardiography
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the comprehensive or the focused CMR protocol should 
be made depending on the quality of the information 
gained from TTE.
Cine images
Standard cine CMR should be performed according to 
the SCMR recommendations22:
r Standard, long- axis, steady state, free- precession 
cine images: four- chamber (horizontal long- axis), 
two- chamber (vertical long- axis) and three- chamber 
(LV outflow tract view).
r A stack of contiguous cines perpendicular to the 
mitral commissures, transecting the principal line 
of coaptation, approximately in a modified LV out-
flow tract plane. These should have a slice thickness 
of 5 mm and no gap, with a temporal resolution of 
≥45 ms (reF.23) (Fig. 2). The main aim is to cover all 
the mitral scallops: A1–P1, A2–P2 and A3–P3. 
Additional commissural cines are acquired per-
pendicular to the lines of coaptation next to each 
of the commissures if the commissures are at an 
oblique angle to the central coaptation line (Fig. 2, 
lines ‘a’ and ‘b’).
r Standard, contiguous, short- axis, LV cine stack with 
extended coverage of the mitral valve.
r Specific short- axis cine perpendicular to the tips of 
the mitral valve in systole (if an optimal image is not 
obtained within the LV stack).
Tips. On cine acquisitions, flow turbulence (for exam-
ple, because of MR jets) produces spin–spin dephasing, 
which can be visualized as hypointense areas within 
the blood pool inside the relevant cardiac chamber. 
This phenomenon allows the observer to make a gross 
qualitative assessment of the MR. If steady state, free- 
precession cines do not show the flow void clearly, fast 
spoiled gradient- recalled echo cines with longer repeti-
tion and echo times can be performed to visualize the 
MR regurgitant flow void better. However, this quali-
tative MR assessment is very susceptible to changes in 
cine pulse sequences and therefore should be used cau-
tiously. Visualization of the MR jet on cine images can, 
however, inform about the aetiology (in addition to cine 
imaging of leaflet anatomy and function) — eccentric 
jets associated with mitral valve leaflet prolapse versus 
a central jet associated with mitral annular dilatation or 
LV dilatation resulting in non- coaptation. Aetiologies of 
MR that are more challenging to diagnose, such as cleft 
mitral valve or perforated leaflets, can also be assessed 
well with a combination of cine and flow imaging. 
Owing to variations in breath holds, a stack of contigu-
ous 5-mm slices can have spatial misalignment, which 
should be carefully judged during scanning. If the cusp 
views are missed during scanning, additional imaging 
can be required.
Flow imaging
2D phase- contrast f low. Currently, the standard 
approach to flow imaging is 2D phase- contrast, velocity- 
encoded imaging. For this approach, one- direction 
(through- plane), motion- encoded, cine gradient- echo 
sequences are used. The preferred sequence parameters 
for 2D phase- contrast imaging are included in the SCMR 
recommendations22:
r Aortic forward flow: a through- plane image plane 
should be placed at the sino- tubular junction in end 
diastole to quantify forward flow for the calculation 
of MR volume (LV stroke volume minus aortic for-
ward flow). This plane should be perpendicular to the 
vessel. In published studies, baseline velocity encod-
ing for aortic flow is 2.0–2.5 m/s. If there is significant 
aliasing, consider increasing the velocity encod-
ing or imaging slightly higher than the previously 
prescribed phase- contrast through-plane.
r MR visual assessment: a long- axis LV outflow track 
phase- contrast stack that is perpendicular to the 
commissures, aligned with the direction of inflow 
and transecting the principal line of coaptation, is 
recommended to visualize MR jets in multiple planes. 
This visualization will clarify the aetiology of the MR. 
Alternatively, an experienced operator can plan a sin-
gle image to capture through- plane flow on the atrial 
side of the valve.
Tips. Signal averaging can be used within the limits of 
breath- holding capabilities. Free breathing, respiratory 
navigator- based signal- averaging techniques can be 
applied to improve the temporal or spatial resolution 
if necessary. The potential for background flow offset 
errors can be reduced by ensuring that phase- contrast 
sequences are acquired with the region of interest (the 
ascending aorta) located at the iso- centre of the magnet 
to minimize any inhomogeneities in the magnetic field24. 
Background phase offset errors can significantly hinder 
the accuracy of flow measurement25, and background 
flow correction processes should be used, such as the 
interpolated automatic sequence26, where available. In 
patients with clinically significant aortic sinus turbulent 
flow, the through- plane image plane can be positioned at 
Box 1 | Clinical questions in CMR assessment of MR
A comprehensive cardiovascular magnetic resonance 
imaging (CMR) study should aim to answer the following 
clinical questions in the assessment of mitral regurgitation 
(MR) for consideration of mitral valvular intervention3.
What is the aetiology of the MR?
rPrimary or secondary
rPresence and location of myocardial infarction on late 
gadolinium enhancement imaging
How severe is the MR?
Are any signs present on imaging in asymptomatic 
patients that might indicate worse outcome if valve 
intervention is delayed?
rDilated left ventricle
rBorderline reduced left ventricular ejection fraction
rDilated left atrium
rProgressive dilatation of the left ventricle and 
worsening of left ventricular function
Has the MR worsened?
rOn longitudinal CMR studies, has the MR volume or MR 
fraction worsened?
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the level of the main pulmonary artery in the ascending 
aorta to quantify aortic forward flow.
In patients with arrhythmias (mostly atrial fibril-
lation), consider performing multiple phase- contrast 
acquisitions and also using arrhythmia- rejection 
sequences. If arrhythmia rejection is used for phase- 
contrast acquisitions, it should be similarly applied to 
the functional cine images. This approach will at least 
provide consistency between the flow and the functional 
measurements. Performing 2D phase- contrast through 
the mitral valve for forward and backward flow quan-
tification is not recommended, mainly because this 
technique remains highly susceptible to through- plane 
mitral annular motion. Furthermore, for dynamic regur-
gitant jets, the acquisition plane cannot be adapted to the 
changing direction of flow.
4D phase- contrast flow. The 2D phase- contrast can 
be swapped for 4D phase- contrast flow if local estab-
lished expertise and technical knowledge exist to quan-
tify transvalvular flow with this approach. 4D- flow 
CMR techniques offer further improvements in the 
assessment of MR and are entering clinical practice27. 
Advantages of MR quantification with the use of 4D- flow 
CMR include single- acquisition, single- sequence, 
retrospective analysis that allows valve tracking to 
account for motion throughout the cardiac cycle as well 
as direct measurement of MR28. Direct quantification 
of the regurgitant jet is particularly useful in patholo-
gies involving multiple valves. A systematic review of 
4D flow- derived methods for MR quantification iden-
tified seven studies that demonstrated that 4D flow- 
derived MR volume is similar to that derived using 
standard CMR methods and even to that derived 
using 3D transoesophageal echocardiography (TOE) 
methods29. In one study, a standard CMR method for 
quantification of MR volume and 4D flow- derived 
methods yielded similar results30.
For 4D- flow CMR, a retrospectively electro cardiogram - 
gated sequence covering the complete cardiac cycle, with 
a temporal resolution of ≥45 ms and a spatial resolution 
of 3 mm × 3 mm × 3 mm or higher is recommended31. 
The field of view should preferably cover the whole left 
ventricle, left atrium and aortic outflow track, including 
the proximal ascending aorta. Before analysis, 4D veloc-
ity data should be carefully checked for errors and, where 
possible, these errors should be resolved.
LGE imaging
LGE imaging should be performed in accordance with 
published guidelines22. Contiguous, short- axis, LV stack 
LGE imaging is recommended, in addition to LGE in the 
three standard long- axis planes.
Analysis
Mitral valve anatomy
Leaflet morphology. A visual assessment should be made 
of all four components of the mitral valve: the anterior 
and posterior leaflets, the annulus, the subvalvular appa-
ratus (papillary muscles), and LV contractility (including 
a Comprehensive protocol Focused, quantitative protocol
Scout imaging
Two-chamber, four-chamber,
three-chamber (LVOT) and RVOT cines
Contiguous short-axis LV stack cines
Contiguous LVOT cines planed perpendicular
to the mitral valve commissures
Additional commissural cines
In-plane 2D phase-contrast contiguous
LVOT stack planed perpendicular to the
mitral valve commissures
LGE imaging: contiguous short-axis LV stack
LGE imaging: two-chamber, four-chamber and
three-chamber (LVOT) views
b
Through-plane 2D phase-contrast through
the pulmonary valve
Through-plane 2D phase-contrast through
the aortic valve
Gadolinium-based contrast injection
& ㄀oYYKVJC NGNFQHXKGYEQXGTKPIVJG
 left ventricle, left atrium and all four valves
Scout imaging
Two-chamber, four-chamber,
three-chamber (LVOT) and RVOT cines
Contiguous short-axis LV stack cines
Through-plane 2D phase-contrast through
the pulmonary valve
Through-plane 2D phase-contrast through
the aortic valve
& ㄀oYYKVJC NGNFQHXKGYEQXGTKPIVJG
left ventricle, left atrium and all four valves10 min
10 min
Targeted
mitral cines
CPF ㄀oY
Essential
Level of recommendation
Strongly recommended
Optional
0QVPGGFGFKH& ㄀oYRGTHQTOGF
(KI | Recommended cardiovascular magnetic resonance imaging protocols for the assessment of mitral 
regurgitation. a | Comprehensive cardiovascular magnetic resonance imaging protocol for the assessment of mitral 
regurgitation. b |(QEWUGFSWCPVKVCVKXGRTQVQEQN.)'NCVGICFQNKPKWOGPJCPEGOGPV.8NGHVXGPVTKEWNCT.816NGHV
XGPVTKEWNCTQWVHNQYVTCEV4816TKIJVXGPVTKEWNCTQWVHNQYVTCEV
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any regional wall- motion abnormalities). Abnormal 
leaflet morphology includes thickening, calcification, 
redundancy, perforation, vegetations, other masses and 
clefts. These abnormalities should be described in detail 
(diffuse versus focal, the size and the leaflet location). 
Abnormal subvalvular morphology can involve chordal 
rupture, thickening, fusion, very large vegetations and 
masses, which should similarly be described in detail 
by size and location. Abnormal annular morphology 
comprises dilatation and/or calcification (seen as signal 
loss). The long- axis stack is best for making the visual 
assessment of the mitral valve leaflets. Longitudinal 
mitral annulus disjunction distance is measured from the 
junction of the left atrial (LA) wall and the mitral valve 
leaflet to the top of the LV wall at end systole in long- axis 
cines and is defined as being clinically significant if the 
distance is ≥1.0 mm.
Leaflet motion. Leaflet motion can be described 
using Carpentier’s classification: type I (normal leaf-
let motion); type II (excessive leaflet motion); and 
type III (restricted leaflet motion), subcategorized 
as type IIIa (restricted during both systole and diastole) 
and type IIIb (restricted only during systole). After a 
comprehensive review of leaflet morphology and motion, 
a possible aetiology for the MR should be described 
according to Table 2. Case studies are provided in Fig. 3. 
The aetiology should be consistent with the overarching 
diagnosis. Sometimes, a mixed picture of both primary 
and secondary MR can exist — for example, pre- existing 
secondary MR caused by dilated cardiomyopathy 
together with a newly torn chord or flail leaflet.
Methods of MR quantification
Several qualitative and quantitative methods of MR 
assessment by CMR are available.
Qualitative assessment. The MR jet should be visual-
ized using both cine and 2D phase- contrast CMR, as 
described in the MR assessment protocol. This approach 
is mainly performed by visual assessment of the MR jet on 
the basis of spin dephasing on cine images. MR jet charac-
terization should include whether the jet is central or 
eccentric, and early, mid, late or pan systolic.
4D- flow CMR allows for visualization of 2D velocity 
vectors in any plane, facilitating a comprehensive assess-
ment of the blood flow dynamics in the left atrium32,33. 
MR jets are dynamic and can change directions dur-
ing systole depending on mitral leaflet adaptations. 
Velocity vector visualization of LA flow coupled with 
cine CMR can help to understand the cause of the MR 
(Fig. 4). Velocity vector visualization of the velocity jet is 
preferred over spin dephasing because it provides truly 
quantitative, directional velocity data. In addition, this 
method can offer a better assessment of the extent of MR 
than is provided by Doppler imaging (which is single 
velocity- encoded imaging), especially when the MR jet 
is swirling within the left atrium.
Anterolateral
commissure
Posteromedial
commissure b
a
1
2
3
4
5
6
Aorta
LAA
Anterior
Posterior
Medial Lateral
A1
P1
A2
P2
A3
P3
(KI | Mitral valve assessment planing during cine cardiovascular magnetic 
resonance imaging acquisition. A contiguous, long- axis, left ventricular outflow tract 
cine cardiovascular magnetic resonance imaging stack should be acquired to visualize 
CPFCUUGUUCNNVJGOKVTCNXCNXGEWURU
#s2#s2CPF#s2'ZVTCRNCPGUVQVJG
commissural line also need to be considered, as demonstrated by the lines ‘a’ and ‘b’. 
L AA , left atrial appendage.
6CDNG | Modified Carpentier’s classification of mitral valve morphology and MR aetiology
Type of leaflet motion Normal mitral valve leaflet Abnormal mitral valve leaflet
Leaflet lesion 
(morphology)
Aetiology: secondary MR Leaflet lesion (morphology) Aetiology: primary MR
Type I: normal leaflet 
motion
Annular dilatation &KNCVGFECTFKQO[QRCVJ[a or 
left atrial dilatation
Leaflet perforation (tear) Endocarditis
Type II: excess leaflet 
motion (prolapse or flail)
– – Elongation (rupture of 
chordae or papillary muscle)
&GIGPGTCVKXGXCNXGFKUGCUG
endocarditis, trauma or 
ischaemic cardiomyopathya
Type IIIa: restricted 
leaflet motion (both 
KP|FKCUVQNGCPFU[UVQNG
– – Leaflet thickening (retraction), 
leaflet calcification, chordal 
thickening (retraction), fusion 
or commissural fusion
Rheumatic heart disease, 
carcinoid heart disease or 
dilated cardiomyopathy
Type IIIb: restricted 
leaflet motion (mainly 
KP|U[UVQNG
Left ventricular 
dilatation (aneurysm)
Ischaemic cardiomyopathya 
or dilated cardiomyopathya
Papillary muscle displacement 
or chordae tethering
Ischaemic cardiomyopathya 
QT|FKNCVGFECTFKQO[QRCVJ[a
MR , mitral regurgitation. aMixed aetiology.
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Quantitative assessment. CMR planimetry of the ana-
tomical mitral regurgitant lesion in patients with MR 
is feasible and allows quantification of MR, which has 
been shown to have good agreement with quantifi-
cation by other invasive and noninvasive methods34. 
Quantification of mitral regurgitant volume and fraction 
is the recommended technique because most clinical 
outcome data are available. The MR volume can be 
obtained by four different methods (Fig. 5).
1. The difference between the LV stroke volume 
(LVSV) calculated using planimetry of cine steady 
LVSV = LVEDV – LVESV = 129 ml
LVSV = LVEDV – LVESV = 87 ml
A1
A2
P1
P2
P3
A2
A3
MR jet
P2 prolapse
LVEDV = 215 ml
LVESV = 86 ml
b  Secondary functional MR
Morphology /4SWCPVK NECVKQP Diagnosis
a  Primary organic MR
Morphology /4SWCPVK NECVKQP Diagnosis
Aetiology
r Primary MR
r Carpentier type II
r P2 prolapse
MR severity
r MR
vol
 = LVSV – AoPC = 23 ml
r MR
RF
 = (MR
vol
 / LVSV) x 100 = 18%
Overall
Mild MR
Aetiology
r 5GEQPFCT[HWPEVKQPCN/4
r Carpentier type IIIb
r 0QPEQCRVCVKQPQHNGC ㄀eVU
UGEQPFCT[VQXGPVTKEWNCT
dilatation resulting in rGUVTKEVKXG
NGC ㄀eVOQVKQP
MR severity
r MR
vol
 = LVSV – AoPC = 36 ml
r MR
RF
 = (MR
vol
 / LVSV) x 100 = 41%
Overall
Moderate MR
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(KI | Case studies of primary and secondary MR . a | Mitral regurgitation (MR) assessment with cardiovascular magnetic 
TGUQPCPEGKOCIKPIKPCRCVKGPVYKVJQTICPKE/42TQNCRUGQHVJG2ECPDGUGGPQPVJGVJTGGEJCODGTXKGYFWTKPIOKF
U[UVQNG
OQTRJQNQI[RCPGNDQVVQOKOCIGCPFVJGTGUWNVKPI/4LGVKUXKUWCNK\GFQPVJGUJQTVCZKUXKGY
OQTRJQNQI[RCPGN
top image). The MR volume (MRvol) is quantified using the standard method: left ventricular stroke volume (LVSV) minus 
aortic phase- contrast forward volume (AoPC). b | MR assessment in a patient with ischaemic cardiomyopathy. Non- 
coaptation owing to ventricular dilatation is seen on the short- axis cines (morphology panel, top images). A through- plane 
RJCUGEQPVTCUVCESWKUKVKQPUJQYUVJGEGPVTCN/4LGV
OQTRJQNQI[RCPGNTKIJVJCPFOKFFNGKOCIG.CVGICFQNKPKWO
enhancement imaging reveals extensive ischaemic myocardial scaring (Morphology panel, right- hand bottom image). 
.8'&8NGHVXGPVTKEWNCTGPFFKCUVQNKEXQNWOG.8'58NGHVXGPVTKEWNCTGPFU[UVQNKEXQNWOG/44(, mitral regurgitation fraction.
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state, free- precession images and the aortic (systolic) 
forward volume obtained by phase- contrast images 
(AoPC); the standard approach.
2. The difference between the LVSV and the RV stroke vol-
ume (RVSV) calculated using planimetry of cine steady 
state, free- precession images; this approach assumes 
no other valve regurgitation or haemodynamically 
significant shunt.
3. The difference between the mitral inflow stroke volume 
and the AoPC.
4. Direct quantification of MR flow by 4D- flow CMR, 
with retrospective mitral valve tracking.
Among these methods, the first is the most widely 
used and has the most prognostic data available12,13. This 
method allows the quantification of the regurgitant vol-
ume without considering regurgitant jet morphology. 
This approach is particularly helpful in patients with 
multiple or eccentric jets, or variable jets through systole. 
In addition, this approach is independent of the effects of 
aortic, tricuspid and pulmonary regurgitation. However, 
this method requires a combination of two acquisitions 
and is, therefore, subject to potential interscan variability. 
If any issues exist with the acquired AoPC to quantify MR 
by the LVSV – AoPC method, an alternative approach is 
to use the pulmonary artery flow (PaPC), as long as no 
intracardiac shunts exist (LVSV – PaPC). Moreover, the 
PaPC approach might be advantageous in certain cir-
cumstances because the pulmonary valve is less often 
diseased and therefore less susceptible to creating errors 
from turbulent flow. In patients with a restrictive ven-
tricular septal defect and a unidirectional left- to-right 
shunt, the LVSV – PaPC method can be used to quan-
tify MR. In patients with a bidirectional flow ventricular 
septal defect, this method is not applicable, and direct 
measurement of the MR jet should be considered. In 
patients with an atrial septal defect, the standard method 
(LVSV – AoPC) is still appropriate for quantification of 
MR and also allows the shunt to be assessed using the 
ratio of the pulmonary and aortic flows (PaPC:AoPC).
The difference in LVSV and RVSV can also be used to 
quantify MR31. However, given the relatively lower pre-
cision with which RVSV is quantified compared with 
LVSV, substantial bias in MR volume can be introduced 
between two operators, resulting in reduced reliabil-
ity35. In addition, this method is not valid for patients 
/K
VTC
NKP
 ㄀o
Y

O
NU

Systole Diastole
'PFFKCUVQNG 'CTN[U[UVQNG /KFU[UVQNG .CVGU[UVQNG
MVSV = 33 ON
MR = 27 ON
(KI | Time- resolved velocity vector visualization with CMR of dynamically changing MR jet. The top row shows 
cardiovascular magnetic resonance imaging (CMR) of three- chamber cines acquired during four phases of the cardiac 
cycle: end diastole, early systole, mid systole and late systole. The second row of images shows velocity vectors in the left 
CVTKWOCPFVJGNGHVXGPVTKENGUWRGTKORQUGFQPVJGVJTGGEJCODGTEKPGU6JGUGKOCIGUCNNQYVJGXKUWCNK\CVKQPQHVJG#s2
UECNNQRUFGOQPUVTCVKPIGCTN[U[UVQNKERTQNCRUGQHVJG2UECNNQR
QTCPIGCTTQYTGUWNVKPIKPCOKVTCNTGIWTIKVCVKQP
/4LGV
FKTGEVGFVQYCTFUVJGOGFKCNKPVGTCVTKCNUGRVWOYJKEJUGVVNGUKPOKFU[UVQNG#NCVGU[UVQNKERQUVGTKQTN[FKTGEVGF/4LGV

[GNNQYCTTQYECPDGCRRTGEKCVGFCUCTGUWNVQH#RTQNCRUG6JG/4XQNWOGKUSWCPVKHKGFKPVJGNQYGTRCPGN6JKUGZCORNG
JKIJNKIJVUJQYEKPG%/4CPFCWIOGPVGFUVTGCONKPGXKUWCNK\CVKQPQHVJG&HNQY%/4ECPJGNRVQOCMGCOQTGF[PCOKE
pathophysiological diagnosis of the cause of MR . MVSV, mitral valve stroke volume.
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Type
Outcome data
Strengths
Limitations
Pathologies in which
/4ECPDGSWCPVK 　eF
Calculation and
sample images
Calculation and
sample images
3WCPVK 　cCVKQPOGVJQF
3WCPVK 　cCVKQPOGVJQF
Standard
LVSV – AoPC 
Indirect
++
r Simple
r No major postprocessing
r Can be used for MR with multiple
jets or eccentric jets
r Prone to errors owing to two
different types of acquisition
r Cause of inconsistency is mainly
variation in the segmentation
of the basal left ventricular cine
slices
r All except for ventricular septal
defects
Cine
LVSV – RVSV
Indirect
–
r Simple
r No need for two acquisitions
r Can be used for MR with multiple
jets or eccentric jets
r RVSV has high segmentation
variability 
r Poor precision
r Cannot be used in aortic, tricuspid
or pulmonary incoherencies
r Solitary MR
2D phase-contrast 
MVPC – AoPC
Indirect
–
r Single type of acquisition
r Quick postprocessing
r Substantial through-plane motion
of the mitral valve can overestimate
OKVTCNHQTYCTF ㄀oY
r Atrial septal defect
r Aortic regurgitation
(MVPC – AoPC
FF+BF
)
r Tricuspid regurgitation
& ㄀oY
Direct MR jet
Direct
–
r&KTGEVSWCPVK NECVKQP
r Can be performed in multiple
pathologies involving shunts and
valvular regurgitations
r Challenging to perform for MR
with multiple jets
r All
Alternative to standard
LVSV – PaPC
Indirect
–
r Similar strengths to those of the
standard method and less susceptible
VQGTTQTUHTQOVWTDWNGPV ㄀oY
r Similar limitations to those of the
standard method and limited to
patients with no major intracardiac
shunt
r Restrictive ventricular septal defect
and a unidirectional left-to-right
shunt
LVSV = 
LVEDV – LVESV
AoPC LVSV = 
LVEDV – LVESV
RVSV = 
RVEDV – RVESV
MVPC AoPC
Retrospective
valve (diastole)
and MR jet tracking
(systole) method
3D MR jet
streamline
visualization and
SWCPVK NECVKQP
LVSV = 
LVEDV – LVESV
PaPC
Type
Outcome data
Strengths
Limitations
Pathologies in which
/4ECPDGSWCPVK 　eF
LVEDV RVEDV
LVESV
LVEDV
LVESV RVESVAoPC AoPC
LVEDV
LVESV PaPC
(KI | Main methods of MR 
quantification by cardiovascular 
magnetic resonance imaging. 
Prognostic and diagnostic 
outcome data are most available 
for the standard method of 
quantifying mitral regurgitation 
(MR) volume (MRvol), which is left 
ventricular stroke volume (LVSV) 
minus aortic phase-contrast 
HQTYCTFXQNWOG
#Q2%1VJGT
methods have particular 
advantages or disadvantages. 
+P|TQWVKPGENKPKECNRTCEVKEGETQUU
checking between methods is 
TGEQOOGPFGF((+$(HQTYCTF
HNQYRNWUDCEMYCTFHNQY.8'&8
left ventricular end-diastolic 
volume; LVESV, left ventricular 
end-systolic volume; MVPC, mitral 
valve phase- contrast stroke 
volume; PaPC, pulmonary artery 
phase-contrast stroke volume; 
48'&8TKIJVXGPVTKEWNCT
end-diastolic volume; RVESV,  
right ventricular end-systolic 
volume; RVSV, right ventricular 
stroke volume.
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with multiple valve lesions or shunt flow as a result of 
ventricular septal defects.
The third method is, in theory, valid for patients with 
multiple valve lesions or shunt flow but, in practice, this 
method often has substantial errors. 2D phase- contrast 
CMR requires static imaging planes that cannot adapt 
to through- plane valve motion or the changing location 
of the mitral valve and the changing direction of inflow 
or regurgitant jets36,37. This method is also susceptible 
to measuring entrained blood already in the left atrium 
as part of the regurgitant jet if the imaging slice is too 
far from the orifice or the region of interest is too large. 
Furthermore, this method requires two acquisitions, 
which can be subject to variability.
The 4D- flow CMR, retrospective valve- tracking 
method (Fig. 6) produces a direct quantification of MR by 
quantifying flow directly at the valve and is valid in the 
presence of multiple valve lesions or shunt flow38. This 
approach overcomes the limitations of the third method 
described above, but acquisition times and postprocess-
ing can be challenging27. In retrospective valve tracking, 
a dynamic reformatted 2D phase- contrast plane is recon-
structed by tracking the mitral annulus over the whole 
cardiac cycle28,32,38. MR jets are quantified by defining a 
systolic reformatted plane perpendicular to the single 
jet or individually for multiple jets. Alternatively, if the 
MR jet is too complex, a reconstructed aortic plane using 
the retrospective valve- tracking method can be used to 
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3WCPVKVCVKXG ㄀oYCPCN[UKU
factoring in automated
valve-motion correction
7
(QTYCTF ㄀oYUGIOGPVCVKQP6
$CEMYCTF ㄀oYUGIOGPVCVKQP5 Valve tracking4
Spatial misalignment correction3.QCF& ㄀oYFCVCCPFTGNGXCPVEKPG1
Manual or
automatic aliasing
correction and
offset correction
using static tissue
2
(KI | 4D- flow cardiovascular magnetic resonance imaging analysis. 
Step 1: load the two- chamber and four- chamber cardiovascular magnetic 
TGUQPCPEGKOCIKPIEKPGU
WRRGTRCPGNCPF&RJCUGEQPVTCUVHNQYCPF&
RJCUGEQPVTCUVFCVC
NQYGTRCPGN5VGRFGRGPFKPIQPVJGUQHVYCTGVQQN
perform manual or automated aliasing and velocity offset corrections with 
the use of the static background tissue. Step 3: an attempt to check for 
URCVKCNOKUCNKIPOGPVDGVYGGPVJGEKPGUCPFVJG&HNQYFCVCUJQWNFDG
OCFGDGECWUGVJGRTGUGPEGQHCP[OCLQTOKUCNKIPOGPVDGVYGGPVJGOYKNN
introduce errors in the quantification of valvular flow. The red arrows 
indicate the spatial misalignment of both the descending aortic flow (in 
systole) and the mitral inflow (in diastole). The green arrows indicate how 
this misalignment has been corrected. Step 4: on both the two- chamber and 
the four- chamber cines, place two landmark points to mark the valve plane. 
This marking should be done for the complete cardiac cycle. Software 
solutions (for example, CAAS software, PIE Medical Imaging, Netherlands) 
can now automatically track the valve over the complete cardiac cycle. 
After ensuring the valve is properly tracked, generate a phase- contrast, 
XCNXWNCTTGHQTOCVVGFRNCPG5VGRUsQPVJGXCNXWNCTTGHQTOCVVGFRNCPG
segment the mitral regurgitant backward flow during left ventricular systole 
and the forward flow during diastole. The regurgitant plane should be 
RGTRGPFKEWNCTVQVJGTGIWTIKVCPVLGV+HOWNVKRNGLGVUGZKUVQPGUJQWNFOCMG
an attempt to evaluate each of them to quantify the total mitral 
regurgitation (MR). Step 7: quantify valvular forward and backward flow 
after accounting for the through- plane motion of the valve plane. Similar 
steps can be used to quantify aortic, tricuspid and pulmonary valvular flows 
YKVJVJGWUGQHVJG&HNQYFCVCUGV
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quantify AoPC. This measurement can then be used 
to quantify MR volume or fraction using the standard 
LVSV – AoPC method.
Finally, in routine practice, cross- checking MR quanti-
fication between methods is useful to reduce uncertainty. 
Particularly in isolated MR, LVSV – AoPC can easily be 
cross- checked with LVSV – RVSV or even LVSV – PaPC.
Volumetric cine analysis
LV and RV volume assessment. LV and RV volume quan-
tification is performed according to standard methods33. 
The use of analysis software that allows demarcation 
of the base of the ventricles on the long- axis images is 
recommended. LV end- diastolic volume and LVSV are 
used for the standard method of MR volume calculation 
(see below) as well as for determining the degree of LV 
dilatation in response to MR.
LA assessment. LA volumes should be assessed using 
the biplane area–length method39–41. On the basis of the 
cine long- axis four- chamber and two- chamber views, 
the contours of the endocardial borders are delineated 
at end systole (LA diastole). The LA appendage should 
be included in the atrial volume, but the pulmonary 
veins should be excluded. 3D volume methods on the 
basis of short- axis stacks can be performed and are 
more accurate than the 2D biplane method, but both 
the acquisition and postprocessing are much more time 
consuming.
CMR reporting of MR assessment
A CMR report for MR assessment should include 
the standard reporting details described in the CMR 
standards (box 2). The report should include a detailed 
description of morphological and/or functional charac-
teristics of the mitral leaflets, annulus and chordae 
tendineae. In addition, a description of MR jet charac-
teristics (such as central or eccentric; single or multiple; 
early, mid, late or pan systolic) and expansion in the left 
atrium should be included. The CMR report should 
mention the method of MR quantification. If any non-
standard method is chosen, a clear reason why it was 
adopted should be detailed in the report. In the report 
conclusion, adding the morphological and functional 
correlates to the aetiology of the MR, including primary 
or secondary MR and Carpentier’s functional class of 
MR, is helpful.
Reference values to grade MR
Owing to the lack of a true gold standard, which method 
quantifies MR severity with the highest degree of accu-
racy and reliability is unknown. Nonetheless, prognostic 
studies that demonstrate the superiority of CMR quan-
tification of MR can guide clinical decision- making. 
Echocardiographic quantification of MR generally 
shows a bias towards much higher regurgitant volumes 
than those measured by CMR, so the thresholds that 
define severity might need to differ according to the 
imaging technique used. Table 3 details the methods 
and CMR grading used in the three most relevant pub-
lications so far. If other methods are used to quantify 
MR volume or regurgitation fraction, such as 4D- flow 
CMR, similar thresholds could be used. However, future 
large studies are needed to compare different MR quan-
tification methods directly with outcomes to clarify the 
applicability of the thresholds for different methods.
CMR in clinical pathways
In routine clinical pathways, if MR is suspected on the 
basis of clinical signs and symptoms, TTE assessment 
of MR can determine its aetiology, assess its severity 
and measure the haemodynamic consequences on the 
left ventricle. In patients in whom the degree of MR is 
uncertain, especially between moderate and severe MR, 
further tests are considered. TOE has been the second- 
line imaging test not only for clarification of the aetiol-
ogy but also for assessing the degree of MR. TOE has 
$QZ| CMR report for MR assessment
Include information on the indication for cardiovascular magnetic resonance 
imaging (CMR)
CMR protocol used for mitral regurgitation (MR) assessment:
rNoncontrast MR assessment
rContrast MR assessment
rHeart rate and blood pressure
Standard CMR report, including details on:
rLeft ventricular and right ventricular regional and global function
rPresence of scarring or infarction on late gadolinium enhancement imaging, with 
description of myocardial viability and left atrial (LA) and right atrial size
rAny other pathology identified should be described
Mitral valve qualitative assessment
rA detailed description of mitral valve characteristics, including: 
 - Leaflets: thickened (base, mid or tips), calcification, restricted motion, tethered, 
bowing, prolapse or flail
 - Annulus: annular calcification, fibrosis on late gadolinium enhancement imaging, 
mitral annular disjunction >1 mm
 - Chordae: thickened, short, restrictive, rupture or tear
rA description of MR jet characteristics:
 - Central or eccentric MR jet
 - Single or multiple MR jets
 - Early, mid, late or pan systolic
 - MR jet expansion in the left atrium
Quantitative analysis of complete CMR study
rDimensions, mass (corrected for body surface area) and function
 - Left ventricle: end- diastolic volume, end- systolic volume, stroke volume, ejection 
fraction and mass
 - Right ventricle: end- diastolic volume, end- systolic volume, stroke volume and 
ejection fraction
rMR (method used to quantify)
 - MR volume (ml)
 - Regurgitation fraction (%)
rLA size
 - LA volume (ml)
 - LA annulus diameter (cm)
Final report conclusions
rMorphological diagnosis of the aetiology of MR (primary or secondary) and/or 
Carpentier’s functional class of MR
rDegree of MR
rDegree of LA dilatation
rLeft ventricular function and degree of dilatation
rPresence, location and degree of myocardial scar or replacement fibrosis
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higher spatial and temporal resolution than either TTE 
or CMR. However, TOE remains a semi- noninvasive 
test and relies on successful oesophageal intubation. 
Although TOE is widely available and is less expensive 
than CMR, risks are associated with a TOE examina-
tion42. Overall, with the advent of CMR methods for 
MR assessment, the real value of TOE will be in pro-
viding high- resolution 2D and 3D dynamic imaging of 
the mitral apparatus, mitral valve and scallops to inform 
and plan surgical intervention, in guiding mitral valve 
percutaneous interventional procedures and, finally, 
for intraoperative checks before and after mitral valve 
intervention. Importantly, MR volume quantified by 3D 
TOE has a high level of agreement with that obtained by 
standard CMR methods43.
In patients in whom further assessment of MR severity 
is needed, we recommend CMR as a second- line non-
invasive test. CMR is also recommended in asympto-
matic patients with severe MR for further clarification 
of LV and LA volumes. If a clinical decision is made to 
‘wait and watch’, the focused CMR study proposed in this 
Consensus Statement can be used to perform longitudinal 
volumetric and flow assessment to investigate any pro-
gression of the MR and associated volume overload on 
the left ventricle. CMR is not currently recommended for 
further investigation of vegetation in patients with sus-
pected infective endocarditis- associated MR. This lack 
of recommendation is mainly because the current spatial 
resolution of CMR is not high enough, and CMR gener-
ates averaged time- resolved images over several cardiac 
cycles rather than live images. During multidisciplinary 
meetings involving imaging cardiologist–radiologists, 
nonimaging cardiologists and surgeons, we recom-
mend actively discussing all imaging options, including 
CMR- derived MR metrics, to encourage wider familiarity 
with CMR methods. In summary, TTE, TOE and CMR 
are likely to provide complementary information to guide 
treatment and surveillance in patients with MR.
Future directions
The evidence that CMR can be used to quantify MR 
accurately and to predict outcomes12,13 makes CMR 
quantification of MR an attractive tool for future use 
in randomized controlled trials. The benefit of mitral 
valve intervention on the basis of the severity of MR (by 
any modality) has never been studied in a randomized 
controlled trial, even though mitral valve repair is con-
sidered acceptable for asymptomatic patients with a 
repairable mitral valve according to both European and 
US guidelines3,5.
Future clinical studies are also needed to address 
whether theoretically more accurate methods of directly 
quantifying MR, such as retrospective valve tracking 
using 4D- flow CMR data, are superior to the currently 
established methods. A need also exists for widespread 
adoption of robust background flow offset correction 
methods to provide MR practitioners with confidence 
in flow quantification. The inaccuracy of quantification in 
some patients and on some systems is a major barrier 
to the use of CMR both in MR and in valve disease 
more generally. Good CMR thresholds for defining the 
severity of MR are also required, ideally on the basis of 
outcome data. Existing quantitative thresholds borrowed 
from echocardiographic data are unsuitable, with wide 
variation between echocardiography and CMR12,13.
Conclusions
The assessment of MR by CMR has great utility. CMR 
is a robust clinical imaging test for the comprehensive 
assessment of mitral valve morphology and the quantifi-
cation of MR, with high levels of accuracy. Evidence sug-
gests that CMR can be used to guide and inform clinical 
outcomes and prognosis in patients with MR. Emerging 
methods, including 4D- flow CMR, show great promise 
to improve the precision and accuracy of MR quantifica-
tion. However, further studies to investigate the clinical 
benefit of 4D- flow CMR are warranted.
Published online xx xx xxxx
Table 3 | Recommended grading of MR by CMR assessment
Type of MR Grading of severity
Mild Moderate Severe Very severe
Primary MR4( <a MR4( =sa MR4(s
MRvol >sON
MR4( >
Secondary MRvol <ON MRvol =sON MRvol ≥ON –
(TQOreFs,13,. CMR , cardiovascular magnetic resonance imaging; MR , mitral regurgitation; 
MR4(, mitral regurgitation fraction; MRvol, mitral regurgitation volume. 
aNot study- based; 
mainly expert opinion.
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